Ing Renault F1 Team Chooses Appro Xtreme-X Supercomputer

Idera Pharmaceuticals, Inc., Cambridge, Mass., (Nasdaq: IDRA) today reported financial results for the fourth quarter and full year ended December 31, 2007. During 2007 we made substantial progress in advancing our drug candidate pipeline and expanding the potential applications of our TLR-targeted compounds. We initiated a phase 1 clinical trial of our lead candidate for infectious diseases, IMO-2125, in patients with chronic hepatitis C virus infection. We entered into a collaboration with Merck KGaA for the use of our TLR9 agonists, including IMO-2055, for cancer treatment. Under our collaboration with Novartis for asthma and allergies, Novartis identified QAX935, a novel agonist of TLR9, as a lead compound for clinical evaluation. In addition, we advanced studies of our TLR antagonist candidates in preclinical models of autoimmune diseases including lupus and rheumatoid arthritis," said Sudhir Agrawal, D. Phil., CEO and chief scientific officer. "Based on our accomplishments to date, we continue to make progress in achieving our long-term goal of realizing the broad potential of TLR-targeted candidates through our proprietary programs and partnered programs."